Consistent with the above findings 51-54, our study further demonstrated that melatonin and HBO therapies repressed AKT activation induced by oncogenic mutations and then reduced HIF-1 expressions, followed by diminishing the expression of glycolytic enzymes to limit tumor survival and tumorigenesis. The gene discussed is AKT1; the disease is neoplasm.